Person: SARIDAŞ, FURKAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SARIDAŞ
First Name
FURKAN
Name
8 results
Search Results
Now showing 1 - 8 of 8
Publication Real-world experience of ocrelizumab in ms in the Turkish population: A single-center study(Wiley, 2022-07-01) Ceylan, D.; SARIDAŞ, FURKAN; Koç, Erdem; Turan, Orhan; Özkaya, Güven; ÖZKAYA, GÜVEN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-4893-3988; 0000-0001-5945-2317; HSB-2700-2023Publication Sectoral and quadrant evaluation of the peripapillary retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in patients with multiple sclerosis(Galenos Publ House, 2023-12-01) Yazici, Alper; Koç, Emine Rabia; KOÇ, EMİNE RABİA; Sarıdaş, Furkan; SARIDAŞ, FURKAN; Turan, Ömer Faruk; 0000-0002-1367-240X; 0000-0001-5945-2317; JCO-1811-2023; HSB-2700-2023Objective: To evaluate the peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell-inner plexiform layer thickness (GC-IPL) in patients with multiple sclerosis (MS) by sector and quadrant.Materials and Methods: Seventy-eight eyes of 39 patients with MS and 82 eyes of 41 healthy participants were analyzed using spectral domain optical coherence tomography. Our study defined MS eyes with optic neuritis (ON) as MS ON eyes and those without ON as MS non-ON eyes. Comparisons of the GC- IPL and pRNFL thicknesses were assessed and the measurements compared with healthy controls (HCs).Results: The comparison of the average and three quadrants (superior, inferior, and temporal) measurements of the pRNFL thickness and the average and six quadrant measurements of the GC-IPL thickness between the MS ON eyes and the MS non-ON eyes revealed statistically significant differences (P < 0.05). The average and four quadrants thickness of pRNFL and the average and six quadrants thickness of GC-IPL were significantly reduced in a comparison of MS ON vs. HC with MS non-ON vs. HC eyes (P < 0.05).Conclusion: The evaluation of pRNFL and GC-IPL thicknesses in MS ON and MS non-ON eyes may be beneficial in determining the central nervous system axonal integrity.Publication The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis(Taylor & Francis, 2022-03-04) Sarıdaş, Furkan; Ünlü, Havva Tezcan; Çeçener, Gülşah; Egeli, Ünal; Takanlou, Maryam Sabour; Takanlou, Leila Sabour; Tunca, Berrin; Zarifoğlu, Mehmet; Turan, Ömer Faruk; Taşkapılıoğlu, Özlem; SARIDAŞ, FURKAN; ÇEÇENER, GÜLŞAH; EGELİ, ÜNAL; TUNCA, BERRİN; ZARİFOĞLU, MEHMET; TURAN, ÖMER FARUK; Takanlou, Maryam Sabour; Takanlou, Leila Sabour; Taşkapılıoğlu, Özlem; 0000-0001-5945-2317; 0000-0002-0910-4258; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1590-4833; 0000-0002-6361-7150; 0000-0002-1619-6680; HSB-2700-2023; GYU-0252-2022; AAP-9988-2020; AAH-1420-2021; KGL-6846-2024; GRE-6268-2022; ABI-6078-2020; EHN-5825-2022; JDI-6091-2023; EBA-4926-2022Multiple sclerosis (MS) is an inflammatory, autoimmune demyelinating, and neurodegenerative disorder of the central nervous system. Interactions between environmental factors, predisposition genes, and determining genes appear to be involved in its etiology. Epigenetic mechanisms such as microRNA-mediated gene regulation can determine the susceptibility and severity of autoimmune diseases. Therefore, to determine the role of miR-146a and miR-155 in MS and its developmental stages, the expression levels in the serum of MS and clinically isolated syndrome (CIS) patients were compared with those of healthy controls. In the present study, the expression levels of miR-146a and miR-155 were assessed using quantitative Real-Time PCR in blood samples of 15 CIS patients and 61 relapsing-remitting multiple sclerosis (RRMS) patients alongside 32 healthy patients as controls. Furthermore, any associations with the clinicopathologic variables of the patients were also evaluated. Dysregulations were found only in the miR-146a and miR-155 expressions in the RRMS-Control group. When the RRMS patients were evaluated in terms of the characteristics of sex, annual attack rate, age of diagnosis, duration of follow-up, and immunomodulatory treatments used, no significant differences were observed. However, significant dysregulations were identified in miRNA expression in the vitamin D level, EDSS values, and the number of attacks. ROC curve analysis showed that miR-146a and miR-155 were significant in the RRMS-Control group for the area under the curve (AUC). It is possible that miR-146a may be associated with vitamin D deficiency and disease disability, while miR-155 may be associated with the number of attacks.Publication Etiology, clinical characteristics and in-hospital mortality of status epilepticus: Single center experience(Galenos Yayınevi, 2023-03-01) Sarıdaş, Furkan; Mengüç, Bedirhan; Demir, Aylin Bican; Bora, İbrahim; SARIDAŞ, FURKAN; MENGÜÇ, BEDİRHAN; BİCAN DEMİR, AYLİN; BORA, İBRAHİM HAKKI; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; 0000-0001-5945-2317; 0000-0001-6739-8605; HSB-2700-2023; V-7170-2017; JIJ-5059-2023; ENI-7759-2022Objective: Status epilepticus (SE) is a serious neurological emergency that can has high morbidity and mortality rates and requires prompt diagnosis and treatment. There are different etiologies and the prognosis varies multifactorially. The aim of this study was to reveal the etiological causes, clinical features and mortality rates of patients diagnosed with SE at our center.Methods: The records of 234 patients with a diagnosis of SE over the age of 18 who were followed up and treated at our center between 01.01.2015-01.01.2022 were evaluated retrospectively. Using the hospital information operating system database, we identified people hospitalized with an International Classification of Diseases 10th Revision code G41 for SE as the primary diagnosis. Demographic information, clinical characteristics, and discharge results were obtained from medical records.Results: One hundred-twenty (51.3%) female and 114 (48.7%) male patients were evaluated. The top 3 most common etiologic causes were: discontinuation of anti-seizure treatments without advice (n=82), cerebrovascular events (n=50), and meningitis or encephalitis (n=39). Motor seizures were detected in 183 (78.2%) patients, and non-motor seizures were detected in 51 (21.8%) patients. Seizures were suppressed by first-line treatment in 24 patients and by second -line treatments in 135 patients. Seventy-five patients whose seizures could not be suppressed were accepted as refractory SE and 9 died. The mean age of all patients was 55, and 63 of the patients died.Conclusion: In this study, clinical and demographic features, the etiological causes and in the hospital mortality rates of SE followed in a single center in the Turkish population were determined. The most common causes of patients diagnosed with SE were discontinuation of anti-seizure treatments without our recommendation, cerebrovascular diseases and central nervous system infections, respectively. In our center, no relationship was found between age and mortality. The in-hospital mortality rate was 3.9% for all patients (n=234) and 12% for patients with refractory SE (n=75).Publication Probable eculizumab-associated hepatotoxicity in a patient with neuromyelitis optica: A case report(Taylor & Francis Ltd, 2023-08-28) Özen, Pınar Acar; Tuncer, Aslı; KOÇ, EMİNE RABİA; Lazrak, Elhamida Sarra; TURAN, ÖMER FARUK; Faruk, Turan Omer; Furkan, Saridas; SARIDAŞ, FURKAN; 0000-0001-5945-2317; HSB-2700-2023; JCO-3228-2023ObjectivesNeuromyelitis optica (NMO) is an inflammatory, autoimmune and demyelinating disease of the central nervous system and is often characterized by attacks of severe optic neuritis and long segment myelitis. Identifying the disease-specific pathogenic anti-AQP4 autoantibody in NMOSD has allowed the development of highly effective disease-modifying drugs in the treatment phase. Eculizumab is a humanized antibody that binds to complement C5 and inhibits the formation of the C5b-induced membrane attack complex. It is approved for treating many diseases in which tissue damage is accompanied by complement (such as neuromyelitis optica, myasthenia gravis, autoimmune hemolytic anemia and paroxysmal hemoglobinuria).MethodsWe present a patient diagnosed with NMO who developed possible drug-induced liver injury three months after the start of eculizumab treatment.ResultAfter discontinuing eculizumab treatment, liver function tests gradually regressed in a month.ConclusionsEculizumab-associated hepatotoxicity is a previously unreported adverse event in NMOSD patients. Therefore, patients should be monitored for liver function tests during eculizumab treatment, and care should be taken for hepatotoxicity. If hepatotoxicity is detected while under eculizumab treatment, patients should be investigated for other drug use, complementary food supplementation, or possible autoimmune hepatitis, and other potential causes should be excluded.Publication Clinical experiences in psychogenetic nonepileptic seizures between 2003 and 2016 xplaining the diagnosis is the first and most important step of the treatment in clinical practice, and careful patient-doctor communication has a certain positive impact on patients' seizure prognosis(Wiley, 2016-12-01) Demir, Bican A.; Bora, İ.; Sarıdaş, F.; BİCAN DEMİR, AYLİN; BORA, İBRAHİM HAKKI; SARIDAŞ, FURKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0001-6739-8605; 0000-0001-5945-2317; V-7170-2017; JCE-6657-2023; HSB-2700-2023Publication Investigation of miR-146a expression profiles in fecal samples of patients with multiple sclerosis for early diagnosis and treatment(Wolters Kluwer Medknow Publications, 2023-04-01) Ünlü, Havva Tezcan; Sarıdaş, Furkan; Taşkapılıoğlu, Özlem; Çeçener, Gülşah; Egeli, Ünal; Turan, Ömer Faruk; Tunca, Berrin; Zarifoğlu, Mehmet; Ünlü, Havva Tezcan; SARIDAŞ, FURKAN; Taşkapılıoğlu, Özlem; TURAN, ÖMER FARUK; ÇEÇENER, GÜLŞAH; EGELİ, ÜNAL; TUNCA, BERRİN; ZARİFOĞLU, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; 0000-0002-0910-4258; 0000-0001-5945-2317; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-1619-6680; GYU-0252-2022; HSB-2700-2023; EBA-4926-2022; AAP-9988-2020; AAH-1420-2021; JDI-6091-2023; ABI-6078-2020; EHN-5825-2022Introduction: Recent research into multiple sclerosis (MS) has focused on the role of microRNAs (miRNAs) in the development of the disease. This study was designed to analyze miR-146a expression in whole blood and fecal samples of patients with MS. The study aimed to analyze clinical data using the miR-146a expression values obtained. Subjects and Methods: This study included patients with relapsing-remitting MS (RRMS) (n = 53), clinically isolated syndrome (CIS) (n = 15), and healthy controls (n = 26). Total RNA was isolated from the participants' whole blood and fecal samples. RNA extraction was performed using QIAamp RNA Blood Mini Kits for blood samples and RNeasy PowerMicrobiome Kits for feces. miR-146a expressions were studied using real-time polymerase chain reaction. Finally, relative expression was correlated with clinicopathologic factors. Results: MiR-146a expression was significantly decreased in the whole blood (P < 0.001) and fecal samples (P = 0.036) of patients with RRMS. There was no significant difference in the miR-146a expression rate between patients with CIS and controls. Moreover, the miR-146a expression level in patients with RRMS was decreased compared with those with CIS (P < 0.001). A significant association was determined between miR-146a expression and sex in blood samples. When sex stratification was applied to expression values obtained from fecal samples, miR-146a expression was downregulated only in females (P = 0.008). Discussion: miRNAs play an essential role in maintaining the stable course of MS, and this process has some sex-specific differences. Expression of fecal miR-146a may be used as a biomarker to diagnose and predict prognosis in patients with RRMS.Publication Cladribine responsiveness in switched rrms patients(Sage Publications Ltd, 2023-10-01) Tepe, Nermin; Koç, Emine; Sarıdaş, Furkan; Akkoyun, Fatma; Sarı, Ümmu Serpil; Turan, Ömer Faruk; Kabay, Sibel Canbaz; Tokuçoğlu, Figen; KOÇ, EMİNE RABİA; SARIDAŞ, FURKAN; TURAN, ÖMER FARUK; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; 0000-0001-5945-2317; 0000-0002-6752-1519 ; JAL-2843-2023; HSB-2700-2023; JCO-1811-2023